Prostate Cancer
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
October 4, 2023
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
October 3, 2023
Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence.
October 3, 2023
Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
October 3, 2023
Biopsy and Erectile Functional Outcomes of Partial Prostate Ablation: A Systematic Review and Meta-Analysis of Prospective Studies.
October 3, 2023
Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer.
October 3, 2023
The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
October 3, 2023
Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
October 2, 2023
High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.
October 1, 2023
Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
September 29, 2023
T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence.
September 29, 2023